Bavarian Nordic quashes talk of interest in a Big Pharma buyout

Nick Paul Taylor

has downplayed its in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some of its luster over the past year through deals with Bristol-Myers Squibb and Johnson & Johnson, but has no desire to cash in on its moment in the limelight.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS